Cerebral Therapeutics is a clinical-stage pharmaceutical company dedicated to improving the lives of patients with uncontrolled neurological diseases, with an initial focus on refractory epilepsy. The Company utilizes long-term implanted brain drug-device combination therapies to deliver optimal doses of specially formulated anti-seizure medications directly to the target region of the brain. Cerebral Therapeutics is currently exploring direct intracerebroventricular (ICV) administration of a proprietary formulation of an anti-epileptic drug to potentially enhance efficacy and reduce toxicity in adult patients with refractory epilepsy.